MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

CRISPR Therapeutics AG

Gesloten

SectorGezondheidszorg

32.77 -4.07

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

32.17

Max

34.17

Belangrijke statistieken

By Trading Economics

Inkomsten

49M

-37M

Verkoop

34M

35M

EPS

-0.44

Winstmarge

-106.603

Werknemers

393

EBITDA

46M

-60M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+109.36% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.2B

Vorige openingsprijs

36.84

Vorige sluitingsprijs

32.77

Nieuwssentiment

By Acuity

54%

46%

323 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

CRISPR Therapeutics AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 sep 2024, 16:08 UTC

Winsten
Acquisities, Fusies, Overnames

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

26 sep 2024, 14:20 UTC

Acquisities, Fusies, Overnames

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

11 apr 2024, 14:46 UTC

Acquisities, Fusies, Overnames

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

Peer Vergelijking

Prijswijziging

CRISPR Therapeutics AG Prognose

Koersdoel

By TipRanks

109.36% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 71.58 USD  109.36%

Hoogste 120 USD

Laagste 32 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor CRISPR Therapeutics AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

20 ratings

12

Buy

7

Hold

1

Sell

Technische score

By Trading Central

32.96 / 36.93Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

323 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.